Sagent (SGNT) Launches Flumazenil Injection
Sagent Pharmaceuticals, Inc. (Nasdaq: SGNT) announced the launch of Flumazenil Injection, USP, a benzodiazepine antagonist, in two latex-free vial presentations. According to IMS for the 12 months ending September 2012, the US market for Flumazenil Injection, USP approximated $5.6 million. As with all products in Sagent's portfolio, Flumazenil features the Company's PreventIV MeasuresSM packaging and labeling, designed to help reduce medication errors.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- OncoMed Pharma (OMED) to Present Interim Data for Wnt Inhibitors at ESMO
- Genocea Biosciences (GNCA) Announces GEN-003 Phase 2b Met Primary Endpoint as Genital Herpes Treatment
- Marinus Pharma (MRNS) Announces Top-line Results from Phase 2 Study of Ganaxolone in PCDH19 Pediatric Epilepsy
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!